Paul Ambrose, Pharm. D., FIDSA – Dr. Ambrose is currently the President of the Institute for Clinical Pharmacodynamics (ICPD) in Albany, NY. Dr. Ambrose is an honorary research fellow, Infectious Diseases at the Nuffield Department of Medicine, University of Oxford, Oxford, England, United Kingdom. Dr. Amrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Knowledge gained through the use of non-clinical (in vitro and animal) PK-PD infection models may be leveraged with human pharmacokinetic data in order to discriminate between potential dosing regimens and thereby increase the probability of positive clinical outcomes while minimizing the potential for drug-related toxicities. ICPD has successfully utilized this approach for support of regulatory decision-making and as support for Clinical and Laboratory Standards Institute susceptibility breakpoint determinations. Dr. Ambrose is the author of over 90 peer-reviewed scientific publications and approximately 100 scientific abstracts. Dr. Ambrose has served as an editor for four textbooks; most notably the first and second editions of Antimocrobial Pharmacodynamics in Theory and Clinical Practice. Finally, Dr. Ambrose is an editor of Antimicrobial Agents and Chemotherapy.

David Andes, MD – Dr. Andes is an Associate Professor in the Departments of Medicine and Medical Microbiology and Immunology at the University of Wisconsin in Madison, WI. He is Head of the Division of Infectious Diseases and Director of the Infectious Diseases Fellowship Program. The focus of Dr. Andes’ research programs involves identification of strategies to combat antimicrobial (especially antifungal) drug resistance. Study approaches include defining the molecular basis for drug resistance, drug target development, pharmacodynamic strategies, and clinical trial study of resistance epidemiology. He has published his research in more than 300 manuscripts, book chapters, and abstracts. He has been awarded the ASM ICAAC Young Investigator Award, University of Wisconsin Puestow Award, and University of Missouri Alumni awards for his research contributions. Dr. Andes is President of the International Society of Antimicrobial Pharmacology, a member of the American Society of Clinical Investigation, the Infectious Diseases Society of American Program and Candidiasis Guideline Committees, Clinical Laboratory Standards Institute Antifungal Committee, Faculty of 1000, Mycoses Study Group, he is on the editorial boards of Antimicrobial Agents and Chemotherapy, Journal of Infectious Diseases, Virulence, Mayo Clinic Proceedings, Medical Mycology, Diagnostic Microbiology and Infectious Diseases, Current Fungal Infection Reports, Pharmaceutics and is a member of numerous NIH, CDC, and Welcome Trust study sections.

Ralph Corey, MD – Dr. Corey joined the Duke University faculty in 1980 and became involved in clinical research at the DCRI in 2001 after 18 years as program director of the Internal Medicine Residency Training Program. He has over 30 years of experience in infectious disease research and during that time helped create the Staphylococcal aureus bacteremia group (SABG) and the International Collaboration on Endocarditis (ICE). Dr Corey created and now directs the Hubert-Yeargan Center for Global Health at Duke University Medical Center. He was recently named the Gary Hock Professor of Global Health. Dr. Corey’s clinical trial research focuses on Staphylococcus aureus infections including skin and soft tissue infections, hospital-acquired pneumonia, bacteremia and infectious endocarditis. He has also studied pericarditis and tropical diseases such as leishman, malaria, and snake bites. Dr Corey has authored over 220 peer-reviewed publications and several book chapters.

Ron Jones, MD – Dr. Jones is an Adjunct Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts and is President/CEO of JMI Laboratories. He is a fellow in the American Society of Clinical Pathologists, the College of American Pathologists, the American Academy of Microbiology, the Infectious Disease Society of America and numerous other organizations. He has served on or chaired numerous committees or subcommittees of the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) over the last 30 years (recipient of the Eilers Award in 2001, the highest award given by the CLSI), and also as a member of the advisory council for antimicrobial agents of the U.S. Pharmacopeia. Dr. Jones has authored over 1,600 peer-reviewed publications on a variety of topics relating to the comprehensive evaluation of new antimicrobial agents, antimicrobial susceptibility test development, and resistance mechanisms and their phenotypic expression or molecular epidemiology. He has also authored a number of book chapters, hundreds of abstracts, pamphlets, and monographs, sits on the editorial board of several international peer-reviewed journals, and is currently the Editor-in-Chief of Diagnostic Microbiology and Infectious Disease, a well known international publication. He has been the principal global investigator for the SENTRY Antimicrobial Surveillance Program and the MYSTIC Programme, as well as a regional monitor for other resistance surveillance networks (ZAPS, ZAAPS, SMART, LEADER, SPAR, SCOPE, AWARE, etc). Dr. Jones obtained his medical degree from the University of Oregon, where he also served an internship and residency in Anatomic and Clinical Pathology. He is board certified in anatomic and clinical pathology by the American Board of Pathology.

Richard White, Ph. D. – Dr. White is a consultant to the biotech industry. After a post-doctoral fellowship on microbial biochemistry at Oxford, he began a career in infectious disease drug discovery. He has over 28 years of experience in the pharmaceutical industry holding positions of increasing responsibility at Lepetit, Glaxo, Lederle and finally at Bristol-Myers Squibb (BMS). At BMS, he was Vice President in charge of Infectious Disease Drug Discovery and was involved with the discovery/ development of the cephalosporins cefepime and cefprozil, as well as the AIDS drugs Videx® and Zerit®. Following this, Dr. White accepted a position at Versicor, where he became Chief Scientific Officer. He played a role in licensing and development of dalbavancin and anidulafungin, taking Versicor public, merging with Biosearch Italia to create Vicuron, and ultimately achieving a market capital of $1.9 billion when the company was sold to Pfizer in 2005. His research interests focus on the mechanism of action of and resistance to antimicrobial drugs, and the special role that natural products have played in treating infectious diseases. He was educated in England where he received his undergraduate degree in Biochemistry from the University of Manchester, and a Ph.D. in Microbial Biochemistry from the University of Oxford.